Laboratory Reference Grade Compounds
⚡ Multi-Compound Synergy Engine · 15% Kit Savings · Live Stoichiometry

Peptide Stacks & Regimens Studio

Precision multi-peptide research cycles engineered with separate physical lyophilized vials. Features interactive diluent stoichiometry, live U-100 syringe graduation visualizers, synchronized 7-day administration schedules, and 1-click complete kit fulfillment.

💧Stoichiometry Station
💉U-100 Meniscus Visualizer
📅7-Day AM/PM Schedule Sync
📦1-Click Medusa Kit Builder
⚡ Interactive Stacking & Compatibility Studio·Database-Grounded Multi-Product Engine
30 Compounds · 2 in Active Regimen

Peptide Stacking & Multi-Product Compatibility Studio

Evaluate whether multiple separate products are safe, synergistic, or contraindicated to run together in your research protocol. Search our catalog, discover verified compatible stacking partners, and generate synchronized co-administration protocols.

1. Stack:Multi-product protocol: checking if separate vials are safe & synergistic to run together.
2. Blend:Single physical vial: active peptides pre-mixed & lyophilized together in 1 cake.
3. Bundle:Commercial selling offer: 15% discount for buying all required vials & supplies together.
🚀 Quick Verified Regimen Presets:
🧪 Active Selected Stack Compounds (2 / 4 Vials):
Click any tag to focus or remove (min 1, max 4)
Vial #1GHK-Cu (Copper Tripeptide-1)(Cellular Remodeling & Cosmetic)
Vial #2BPC-157 (Pentadecapeptide)(Tissue Repair & Healing)

🔍 Search Peptides to Stack:

Type any compound name, target receptor, or biological indication to see stack options.

Filter:
BPC-157· Tissue Repair & Healing
Target: VEGFR2, FAK-Paxillin, Growth Hormone Receptor Upregulation
TB-500· Tissue Repair & Healing
Target: Actin-Sequestering Peptide (G-Actin / F-Actin balance)
CJC-1295 No DAC· Somatotropic GH Axis
Target: GHRH Receptor (Growth Hormone Releasing Hormone)
Ipamorelin· Somatotropic GH Axis
Target: GHS-R1a (Ghrelin Receptor / Growth Hormone Secretagogue)
Tirzepatide· Metabolic & Incretin
Target: Dual GLP-1 & GIP Receptor Co-Agonist
Semaglutide· Metabolic & Incretin
Target: Selective GLP-1 Receptor Agonist
Retatrutide· Metabolic & Incretin
Target: Triple GLP-1 / GIP / Glucagon Receptor Agonist
AOD-9604· Metabolic & Lipolysis
Target: Beta-3 Adrenergic Receptor Activation (GH C-Terminal 177-191)
GHK-Cu· Cellular Remodeling & Cosmetic
Target: Extracellular Matrix Fibroblast Signaling & Gene Expression Reset
Epithalon· Cellular Longevity & Telomeres
Target: Pineal Gland Epithalamic Peptide / Telomerase Activator
NAD+· Cellular Bioenergetics
Target: Mitochondrial Complex I / Sirtuin Sirt1-7 / PARP Cofactor
Glutathione· Antioxidant & Detoxification
Target: Intracellular Redox Buffer / Phase II Hepatic Conjugation
Semax· Cognitive & Neurogenesis
Target: TrkB / BDNF / Melanocortin Receptors (Non-hormonotropic)
Selank· Cognitive & Anxiolytic
Target: GABA-A / Enkephalinase Inhibition / IL-6 Modulation
Melanotan II· Photoprotection & Melanogenesis
Target: MC1R, MC3R, MC4R, MC5R Agonist
PT-141· Sexual Function & Melanocortin
Target: Selective Central MC4R & MC3R Agonist
GHRP-2· GH Secretagogue
Target: GHS-R1a Non-Selective
GHRP-6· GH Secretagogue
Target: GHS-R1a Non-Selective
Cagrilintide· Metabolic & Incretin
Target: Amylin (AMY1-3) & Calcitonin Receptors
Orforglipron· Metabolic & Incretin
Target: Non-Peptide GLP-1 Receptor Small Molecule
Pemvidutide· Metabolic & Incretin
Target: Balanced 1:1 GLP-1 and Glucagon Receptor Dual Agonist
PEG-MGF· Anabolic & Satellite Cell Activation
Target: IGF-1Ec C-Terminal Autocrine Pathway
IGF-1 LR3· Anabolic & Cellular Hyperplasia
Target: IGF-1 Receptor (IGF-1R) with Reduced Binding Protein Affinity
Follistatin-344· Myostatin & Muscle Hypertrophy
Target: Myostatin (GDF-8) & Activin-A Neutralization
BPC-157 Arg· Tissue Repair & Healing
Target: VEGFR2, FAK-Paxillin, Nitric Oxide Synthesis
Vesugen· Vascular & Microcirculation
Target: Endothelial Epigenetic Histone Complex
Cardiogen· Cardiovascular Repair
Target: Myocardial Epigenetic Transcription
Tesamorelin· Somatotropic GH Axis
Target: Pituitary GHRH Receptor
Thymulin· Immune & Neuro-Inflammation
Target: Thymocyte Surface Receptors & Neuro-Immune Axis
SLU-PP-332· Metabolic & Mitochondrial
Target: Estrogen-Related Receptor Alpha (ERRα)
🌟 Stacking Partner Recommendations for:

Peptides that can be safely stacked with GHK-Cu (Copper Tripeptide-1)

Receptor: Extracellular Matrix Fibroblast Signaling & Gene Expression Reset
🟢 Highly Synergistic Partners (Multi-Pathway Amplification):
BPC-157 (Pentadecapeptide)+93 Synergy
Microvascular & Extracellular Matrix Remodeling Synergy

BPC-157 rapidly generates fresh capillary networks (angiogenesis) to deliver oxygen and amino acids to damaged tissue, while GHK-Cu signals fibroblasts to synthesize new type I/III collagen and elastin while inhibiting TGF-beta scar formation.

Timing: Administer in separate SubQ injections daily
🔵 Compatible Regimen Partners (Non-Interfering Pathways):
TB-500Compatible

Systemic cell migration, microvascular remodeling, scar tissue prevention

Tissue Repair & Healing
CJC-1295 No DACCompatible

Stimulates anterior pituitary GH transcription & physiological pulsatile release

Somatotropic GH Axis
IpamorelinCompatible

Triggers amplified somatotrope vesicular release without raising prolactin or cortisol

Somatotropic GH Axis
TirzepatideCompatible

Glucose-dependent insulinotropic polypeptide + glucagon-like peptide-1 appetite & insulin modulation

Metabolic & Incretin
SemaglutideCompatible

Central satiety signaling, delayed gastric emptying, insulin sensitization

Metabolic & Incretin
RetatrutideCompatible

Triple incretin co-agonism with enhanced hepatic lipid oxidation and energy expenditure

Metabolic & Incretin
🟢 Synergistic Stack (100% Recommended)Synergy Index: 93/100

Synergistic Multi-Pathway Amplification

The selected products exert complementary pharmacological actions across distinct receptor targets, producing therapeutic effects superior to either agent alone.

Commercial Bundle Option
15% Stack Bundle Savings
📋 Complete Co-Administration Protocol for This Stack:
🌅 Fasted Morning Window:

BPC-157: 250–500 mcg SubQ

🌙 Pre-Bed Window:

GHK-Cu: 1.5–2.5 mg SubQ (deep subcutaneous or rotate into glute)

📅 Weekly Cadence:

Daily (7 days/week) for 6 weeks.

⏳ Cycle Length & Washout:

6 to 8 weeks on · 4 weeks off

⚠️ Syringe Directive:Strictly separate syringes. Copper chelate has deep blue color; do not mix.
🔬 Pairwise Pharmacodynamic Matrix (1 Compound Pairs):

GHK-Cu + BPC-157

synergistic · 93% Match
Microvascular & Extracellular Matrix Remodeling Synergy

BPC-157 rapidly generates fresh capillary networks (angiogenesis) to deliver oxygen and amino acids to damaged tissue, while GHK-Cu signals fibroblasts to synthesize new type I/III collagen and elastin while inhibiting TGF-beta scar formation.

⏱️ Timing & Scheduling Protocol:

Administer in separate SubQ injections daily. BPC-157 morning, GHK-Cu evening, or staggered by at least 2 hours.

🛡️ Safety & Needle Separation Rule:

Do NOT combine concentrated copper peptide with acidic peptide solutions in the same syringe.

Evidence Grounding: Oxid Med Cell Longev / J Biomater Sci
🔬 Precision Multi-Vial Laboratory Suite

Synchronized Stoichiometry, Syringe Calibrator & Kit Builder

Live stoichiometric recalculations, syringe tick marks, and 1-click kit fulfillment for all 2 active vials in this regimen.

Dual-Channel Multi-Vial Syringe Calibration

Dual-Channel Reconstitution & Stoichiometry Station

Independent volumetric stoichiometry, fluid graduation, and U-100 syringe barrel calibration for each constituent physical vial.

Interactive Syringe Calibration & Reconstitution Stoichiometry— GHK-Cu (Copper Tripeptide-1)

Constituent Channel #1 of 2 (GHK-Cu (Copper Tripeptide-1))

U-100 Micro-Plunger
1. Compound Mass25 mg
mg
Vials:
2. Diluent Volume1.0 mL
mL
Quick:
3. Target Assay Dose4.0 Units
Presets:
Dissolution Vial
25.0 mg/mL1.0 mL
25mg / 1mL
Syringe: 100 U (1.0 mL Workhorse)
4.0 Units (0.040 mL)
01020304050607080901004.0 U
0 U100 U
💡Micro-Dose Accuracy: Low draw (4.0 U). A 30 U (0.3 mL) barrel provides 3× optical tick resolution.
Selected Dose
1 mg
1000 µg active mass
Injection Volume
0.040 mL
40 µL draw
U-100 Syringe Mark
4.0 Units
Barrel Graduation
Single Vial Yield
~25.0 Doses
25 days at 1x Daily (or cyclical 30-day research blocks)

Clinical Trial Titration & Escalation Schedules

Benchmark protocols from peer-reviewed clinical trials & institutional investigational programs.

Analytical Titration Schedule•Target: GHK-Cu (Copper Tripeptide-1)•1x Daily (or cyclical 30-day research blocks)
Escalation Stage & PhaseTarget DoseU-100 Mark (25mg / 1.0mL)CadenceSyringe Sync
Phase 1: Micro-Dose Initiation (Days 1–7)1.0 mg daily (1000 mcg)4.0 Units(0.04 mL)1x Daily (SubQ)
Phase 2: Full Regenerative Block (Days 8–30)2.0 mg daily (2000 mcg)8.0 Units(0.08 mL)1x Daily (SubQ)
Phase 3: Copper Homeostasis Washout (Days 31–60)Cycle Washout0.0 Units(0.00 mL)Zero dosing
Reagent & Consumables Supply Inventory PlanningBased on 25mg vial strength & Analytical Titration Schedule
12-Week Initiation & Escalation CycleTotal: 0.0 mg
Active Vials (25mg):1 vials
Sterile Syringes:12 U-100
BAC Water (10mL):1 bottles
Alcohol Swabs:24 pads
24-Week Comprehensive Extended CycleTotal: 0.0 mg
Active Vials (25mg):1 vials
Sterile Syringes:24 U-100
BAC Water (10mL):1 bottles
Alcohol Swabs:48 pads
Standard U-100 Insulin Syringe (100 units = 1.0 mL)
Target: 5.0 units (0.05 mL)
Research DoseVolume (mL)U-100 Syringe Graduation Mark
500 mcg (Micro Calibration)0.025 mL2.5 Units
2.5 units (0.025 mL) on U-100 syringe
1.00 mg (Standard Target)0.050 mL5 Units
5.0 units (0.05 mL) on U-100 syringe
2.00 mg (High Output Target)0.10 mL10 Units
10.0 units (0.10 mL) on U-100 syringe
3.00 mg (Ceiling Protocol)0.15 mL15 Units
15.0 units (0.15 mL) on U-100 syringe
Calibrated Administration Instrument & Needle Hardware Specification
RUO Standard
Aliquoting Needle
31G Ultra-Fine (0.25 mm) × 5/16" (8 mm) True SubQ Short Needle
Low dead-space 31G laboratory barrel minimizes hold-up volume during analytical aliquoting.
Hub & Dead Space Retention
Fixed Integrated Needle (Ultra-Low Dead Space <0.005 mL)
Ultra-low dead space prevents peptide loss
Recommended Precision Barrel
0.3 mL (30-unit) or 0.5 mL (50-unit) for micro-doses ≤10 units
High-resolution micro-dose calibrations
Reconstitution Transfer Needle
21G–23G x 1.5" sterile needle for diluent extraction and vial wall transfer
Sterile diluent transfer down glass wall
🧪 Aseptic Reconstitution Directive (GHK-Cu (Copper Tripeptide-1)):

Add 2.5 mL Bacteriostatic Water slowly. Solution immediately turns characteristic deep royal blue. Swirl gently for 30 seconds. Do not sonicate, freeze-thaw repeatedly, or vortex.

⚠️ Non-Negotiable Aseptic Stacking Rules
1. Zero Cross-Vial Needle Reuse

Never re-insert a needle into Vial B after drawing from Vial A. Doing so introduces cross-compound enzymes and permanently ruins lot purity.

2. Independent Sterile Syringes

Always use separate U-100 insulin syringes for each constituent compound. Ensure both syringes are labeled before administration.

3. Isolated Assay Channels

Dispense constituent peptides into isolated in-vitro assay channels or separate analytical vessels to prevent unquantified cross-reactivity prior to scheduled observation.

Need in-depth single-vial titration schedules or printable lab dossiers?
Related Research Resources

Explore Companion Dosage Charts & Compound Monographs